Silence Therapeutics (SLN) Return on Sales (2024 - 2026)

Silence Therapeutics (SLN) has 3 years of Return on Sales data on file, last reported at 0.35% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 165.0% year-over-year to 0.35%; the trailing twelve-month figure through Mar 2026 stood at 0.89% (down 87.0% YoY), and the FY2025 full-year result was 1.59%, down 158.0% from the prior year.
• Return on Sales improved to 0.35% in Q1 2026, from 3.46% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q4 2024 to a low of 3.46% in Q4 2025.
• A 3-year average of 0.98% and a median of 0.35% in 2026 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales tumbled 347 bps in 2025 and surged 165 bps in 2026, its largest moves.
• Tracing SLN's Return on Sales over 3 years: stood at 0.01% in 2024, then plunged by 36204 bps to 3.46% in 2025, then soared by 90 bps to 0.35% in 2026.
• Business Quant data shows SLN's Return on Sales at 0.35% in Q1 2026, 3.46% in Q4 2025, and 1.32% in Q3 2025.